-+ 0.00%
-+ 0.00%
-+ 0.00%

Liminatus Pharma appeals Nasdaq delisting notice, trading suspension set May 29

PUBT·05/22/2026 00:28:38
Listen to the news
Liminatus Pharma appeals Nasdaq delisting notice, trading suspension set May 29
  • Liminatus Pharma received a Nasdaq delisting notice on May 20, 2026, tied to failures to meet minimum market value thresholds for listed securities and publicly held shares.
  • Trading in the common stock and warrants is set to be suspended at the open on May 29, 2026, unless an appeal is requested by May 27, 2026.
  • An appeal request would pause the suspension and delisting process while the matter is reviewed by a Nasdaq hearings panel.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Liminatus Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605212028PRIMZONEFULLFEED9725162) on May 22, 2026, and is solely responsible for the information contained therein.